Rishi Surana

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kimberly J. Perez · 7 shared papers, 2022–2026 · strength 1.52
   • Paper Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia. DOI 10.21037/jgo-2026-0221↗
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
2. Harshabad Singh · 6 shared papers, 2022–2026 · strength 0.89
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
3. Brian Matthew Wolpin · 6 shared papers, 2022–2026 · strength 0.89
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
4. James M. Cleary · 6 shared papers, 2022–2026 · strength 0.89
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
5. Andrew J. Aguirre · 5 shared papers, 2022–2026 · strength 0.75
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
6. Jonathan Andrew Nowak · 5 shared papers, 2023–2026 · strength 0.74
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
7. Douglas Adam Rubinson · 5 shared papers, 2022–2026 · strength 0.73
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. DOI 10.3390/cancers14246223↗
8. Srivatsan Raghavan · 4 shared papers, 2023–2026 · strength 0.61
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
9. Brandon M. Huffman · 4 shared papers, 2022–2025 · strength 0.58
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
   • Paper Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. DOI 10.3390/cancers14246223↗
10. Robert A. Wolff · 3 shared papers, 2021–2026 · strength 0.52
    • Paper Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. DOI 10.1093/oncolo/oyag071↗
    • Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
11. Shubham Pant · 3 shared papers, 2021–2026 · strength 0.52
    • Paper Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. DOI 10.1093/oncolo/oyag071↗
    • Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
12. Thomas Adam Abrams · 3 shared papers, 2024–2026 · strength 0.47
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
13. Andressa Dias Costa · 3 shared papers, 2024–2026 · strength 0.47
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
14. Kimmie Ng · 3 shared papers, 2023–2026 · strength 0.46
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-22-3930↗
15. Rachna T. Shroff · 3 shared papers, 2020–2024 · strength 0.44
    • Paper Pancreatic cancer. DOI 10.1016/s0140-6736(20)30974-0↗
    • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
16. Matthew B.B. Yurgelun · 3 shared papers, 2023–2025 · strength 0.41
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
    • Paper Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-22-3930↗
17. Brandon George Smaglo · 2 shared papers, 2023–2026 · strength 0.40
    • Paper Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. DOI 10.1093/oncolo/oyag071↗
    • Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
18. Channing J. Der · 2 shared papers, 2025–2026 · strength 0.39
    • Paper Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. DOI 10.1093/oncolo/oyag071↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
19. Michael James Overman · 2 shared papers, 2021–2026 · strength 0.36
    • Paper Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. DOI 10.1093/oncolo/oyag071↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
20. ANDREA C Enzinger · 2 shared papers, 2025–2026 · strength 0.33
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
21. Hannah L. Williams · 2 shared papers, 2024–2025 · strength 0.31
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
22. Jane Elizabeth Rogers · 2 shared papers, 2021–2023 · strength 0.29
    • Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
23. Leah H. Biller · 2 shared papers, 2024–2025 · strength 0.29
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
24. Stephanie K. Dougan · 2 shared papers, 2024 · strength 0.29
    • Paper Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-24-1164↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
25. Jonathan D. Mizrahi · 2 shared papers, 2020–2021 · strength 0.29
    • Paper Pancreatic cancer. DOI 10.1016/s0140-6736(20)30974-0↗
    • Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.